ZIM Laboratories’ wholly owned European Subsidiary -- SIA ZIM Laboratories has received Marketing Authorisation (MA) from INFARMED (Portugal) -- Portuguese National Authority of Medicines and Health Products for one of ZIM’s New Innovative Products (NIP) ‘Azithromycin for Oral Suspension 200 mg/5ml’ in Portugal.
This is the 1st Marketing Authorisation for ZIM for its New Innovative Products for Europe. Azithromycin Oral Suspension is differentiated in taste masked suspension dosage form which benefits patients who have difficulty in swallowing and children who have difficulty with bitter taste. According to IQVIA, the EU market size for this product in 2022 was around $300 million. Additionally, other target markets for ZIM such as SE Asia & Oceania, Latin America and MENA have a combined market size of around $900 million.
ZIM Laboratories manufactures, formulates, and distributes drug delivery systems to develops generic pharmaceutical products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: